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ABSTRACT
Hepatitis B virus (HBV) infection is a huge problem in the worldwide as well as in Turkey. It has hepatotrophic and lym-
photropic capacity, and can cause hepatocellular carcinoma (HCC) and lymphoma. HCC is the most prevalent primary 
malignity of liver. Some studies have been reported that HBV is more common in patient with lymphoma. We present a 
case with lymphoma diagnosed with liver biopsy which was performed for chronic HBV infection. J Microbiol Infect Dis 
2014;4(2): 75-77
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Kronik Hepatit B için karaciğer biyopsisi yapılarak tanı konan nadir bir lenfoma olgusu
ÖZET
Hepatit B virüsü (HBV) Türkiye de dahil olmak üzere dünya çapında, ciddi bir problemdir. Virüsün hepatotropik ve len-
fotropik özelliğinin olması, en yaygın görülen primer malignitesi olan hepatosellüler kanser (HCC) ve lenfoma riskini 
artırmaktadır. Lenfoma hastalarında HBV taşıyıcılığı sıklığının fazla olduğunu gösteren çeşitli çalışmalar mevcuttur. Bu 
vakada kronik hepatit B ile takip edilen karaciğer biyopsisi sonunda lenfoma tanısı alan olgu sunulmuştur. 
Anahtar kelimeler: Lenfoma, hepatit B, biyopsi
INTRODUCTION
Hepatitis B virus (HBV) infection is a common in-
fectious disease worldwide and also in Turkey.1,2 It 
is estimated that approximately 30% of the world’s 
population has had contact with HBV, and 350 mil-
lion of them are HBV carriers.2 The prevalence of 
HBV infection is 4% in Turkey.1 The possibility of 
cirrhosis and hepatocellular carcinoma (HCC) in-
creases among the carriers of HBV because of its 
hepatotropic characteristic. Also HBV replication 
has been shown in the lymphoid cells, so HBV in-
fection may have a potential risk of lymphomas.3 A 
cohort study was reported that HBs Ag positivity is 
associated with increased risk of diffuse large B-cell 
lymphoma.4 Similar studies have been published in 
the literature scanned hepatitis markers in patient 
follow-up with lymphoma.5,6 We present a patient 
with chronic HBV infection is diagnosed as inciden-
tally diffuse large B-cell lymphoma in liver.
CASE
A 57 year-old female who had HBs Ag positivity for 
6 years admitted to our department. She had not 
any symptoms and findings for hepatitis or cirrhosis, 
and she denied any symptoms related to malignity 
including loss of weight, fever, night sweating. She 
took non-steroid anti-inflammatory drug for arthral-
gia, and has not got any disease in her medical his-
tory. Also, two of her sisters have been infected with 
HBV.
On the first physical examination, she looked 
overweight and no hepatomegaly, splenomegaly, 
ascites were examined, and any cervical and in-
guinal lymphadenopathies were not found. Other 
physical examination was normal. On her labora-
tory findings; alanine aminotransferase was 27U/ L, 
platelet level was 182,000 per µL, and alpha feto-
protein (AFP) level was 5.1ng/ mL. HBsAg and anti-
Hbe were positive; anti-HCV, anti-HDV and anti-HIV Türe Z, et al. Lymphoma diagnosed with liver biopsy 76
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were negative. HBV DNA level was 47500 IU/ mL, 
and coagulation parameters were in normal limits. 
Ultrasound  revealed  no  hepatomegaly,  but  mag-
netic resonance imaging demonstrated that multiple 
nodular lesions with the largest one of them being 
as 2 cm in size were seen in the liver. Immediately, 
ultrasound-guided liver biopsy was performed to the 
patient, and revealed that histological activity index 
was 6/18, fibrosis was 3/6 according to Ishak score.7 
Also, liver parenchyma contained large number of 
neoplastic lymphocytes (Figure 1A), which were 
positively stained with CD20 (Figure 1B). The pa-
tient diagnosed as diffuse large B-cell lymphoma 
which was primary non-Hodgkin lymphoma (NHL) 
of liver. Positron emission tomography performed 
after five months, reached two cm in size axillary 
lymphadenopathy, which remained undetected in 
physical examination. It was removed surgically; no 
neoplastic involvement was examined by pathologi-
cally.
Figure 1. (A) View of diffuse prolif-
eration of large lymphoid cells with 
prominent nucleoli in the liver pa-
renchyma (Haematoxylin& Eosine, 
magnitude 400x), and (B) imaging 
of  B  lymphocyte  (CD20+,  brown 
color) 
DISCUSSION
Hepatitis B and C viruses have hepatotrophic and 
lymphotropic characteristic. While viral replication 
in these cells is ongoing, frequency of some malig-
nity increases such as lymphoma and HCC. HCC 
represents more than 90% of primary liver cancers. 
Incidence of HCC among people with chronic HBV 
infection ranges from 120 to 180 per 100000 each 
year in female. AFP has insufficient sensitivity and 
specificity for diagnosis of HCC.2,5,8
Primary NHL of liver is extremely rare lympho-
ma, which predominantly arises from B cell. Most 
common radiological presentation is a solitary le-
sion in liver, followed by multiple nodular lesions.9 
Nodules between 1 and 2 cm in size should be stud-
ied with CT and MR and, in case of non-diagnostic 
imaging, undergo nodule biopsy.5
Our patient had multiple nodules in the liver. 
Firstly HCC was considered due to HBV infection; 
however, AFP was in the normal range. Then, liver 
biopsy was performed. Diffuse lymphocytic infiltra-
tion was seen on liver parenchyma, and stained 
with CD20. CD 20 is a pan-B-cell antigenic marker 
which is associated with chemotherpy regimens.10
Although there is no significant association be-
tween NHL and HBsAg in EPIC study,6 HBsAg prev-
alence in patients with NHL was detected 2-3 times 
higher than control group in other studies.5 It should 
be planned a comprehensive study to clear up this 
problem about genetically predisposition and host 
factors.
The specificity of our case is that the patient 
was diagnosed as large cell lymphoma when her 
liver biopsy was performed for chronic HBV infec-
tion. When a mass in the liver was detected in pa-
tients with HBV, lymphoma should be also consid-
ered along with HCC.
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